CD274 and diffuse large B-cell lymphoma: Durvalumab, a humanized IgG1 anti-PD-L1 antibody, in combination with R-CHOP, has demonstrated a CR rate of 54% in treatment-naïve DLBCL patients [93], and has shown a fair activity in combination with ibrutinib in relapsed refractory DLBCL patients [94].